Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J. Vasey PA, et al. Among authors: burtles s. Clin Cancer Res. 1999 Jan;5(1):83-94. Clin Cancer Res. 1999. PMID: 9918206 Clinical Trial.
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Blackie R, Schatzlein A, Jodrell D, Bissett D, Calvert H, Lind M, Robbins A, Burtles S, Duncan R, Cassidy J. Seymour LW, et al. Among authors: burtles s. Int J Oncol. 2009 Jun;34(6):1629-36. doi: 10.3892/ijo_00000293. Int J Oncol. 2009. PMID: 19424581 Clinical Trial.
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.
Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ; Cancer Research Campaign Phase I/II Clinical Trials committee. Seymour LW, et al. Among authors: burtles s. J Clin Oncol. 2002 Mar 15;20(6):1668-76. doi: 10.1200/JCO.2002.20.6.1668. J Clin Oncol. 2002. PMID: 11896118 Clinical Trial.
Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. The Cancer Research Campaign (CRC) Phase I/II Clinical Trials Committee and the European Organization for Research and Treatment of Cancer (EORTC) New Drug Development Office.
Burtles SS, Newell DR, Henrar RE, Connors TA. Burtles SS, et al. Eur J Cancer. 1995;31A(3):408-10. doi: 10.1016/0959-8049(94)00483-l. Eur J Cancer. 1995. PMID: 7786609 No abstract available.
18 results